Subtotal £0.00
Subscribe to out newsletter today to receive latest news.
- Phone:+44 7490 342983
- Email:info@micjeffonpharmacy.com
- United Kingdom
Subscribe to out newsletter today to receive latest news.
Crizonix contains the cancer drug Crizotinib, a kinase inhibitor indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive
Availability: In Stock
Crizotinib spc contains the cancer drug Crizotinib, a kinase inhibitor indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is FDA-approved as a therapy for both ALK-positive and ROS1-positive metastatic NSCLC. It is the only FDA-approved drug for ROS 1-positive NSCLC.
Dosage and Administration
Each pack of crizotinib spc contains 28 x 250mg capsules.
Your doctor will prescribe you a specific dose. Your doctor should also advise how often to take Crizotinib, when to take Crizotinib and how long to take Crizotinib.
Precautions
Crizonix can be used by:
CYP3A Inhibitors: Concurrent use of crizotinib spc avoided with strong CYP3A inhibitors including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and voriconazole
CYP3A Inducers: Use of crizotinib spc should avoid with strong CYP3A inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John’s Wort
The most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.
